Cargando…

Drugs that slow the progression of diabetic kidney disease: are renoprotective effects attenuated in heart failure?

[Figure: see text]

Detalles Bibliográficos
Autores principales:	Packer, Milton, Siddiqi, Tariq Jamal, Butler, Javed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Viewpoint
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149530/ https://www.ncbi.nlm.nih.gov/pubmed/36943697 http://dx.doi.org/10.1093/eurheartj/ehad158

Ejemplares similares

Patiromer use in patients with heart failure: lessons and clinical considerations from the DIAMOND trial
por: Butler, Javed, et al.
Publicado: (2022)

Totality of evidence in trials of sodium–glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice
por: Butler, Javed, et al.
Publicado: (2020)

Heart Failure in Pregnancy: A Problem Hiding in Plain Sight
por: Stergiopoulos, Kathleen, et al.
Publicado: (2019)

Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER‐like endpoint definitions
por: Anker, Stefan D., et al.
Publicado: (2022)

A patient-centred, comprehensive model for the care for heart failure: the 360° heart failure centre
por: Halatchev, Ilia G, et al.
Publicado: (2020)

Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction
por: Straw, Sam, et al.
Publicado: (2021)

The Dawn of the Invasive Heart Failure Specialist
por: Kassi, Mahwash
Publicado: (2021)

Hypotension and Renal Dysfunction: The Ghosts of Heart Failure
por: Villacorta Junior, Humberto, et al.
Publicado: (2017)

Heart failure classification in clinical practice: time to redefine?
por: Hu, Kai, et al.
Publicado: (2022)

Paradigm-HF: a Paradigm Shift in Heart Failure Treatment?
por: Correia, Luis Cláudio Lemos, et al.
Publicado: (2016)

Cognitive Deficit in Heart Failure and the Benefits of Aerobic Physical Activity
por: Rêgo, Maria Luíza de Medeiros, et al.
Publicado: (2018)

Enteric Fever: A Slow Response to an Old Plague
por: Franco-Paredes, Carlos, et al.
Publicado: (2016)

Clinical Update of the Latest Evidence for CardioMEMS Pulmonary Artery Pressure Monitoring in Patients with Chronic Heart Failure: A Promising System for Remote Heart Failure Care
por: Brugts, Jasper J., et al.
Publicado: (2021)

Endocrine system dysfunction and chronic heart failure: a clinical perspective
por: Lisco, Giuseppe, et al.
Publicado: (2021)

Noninvasive Bioimpedance Methods From the Viewpoint of Remote Monitoring in Heart Failure
por: Krzesinski, Pawel, et al.
Publicado: (2021)

The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context
por: McMurray, John J V, et al.
Publicado: (2020)

Predicting arrhythmias in primary prevention heart failure patients: picking up the fragments
por: Engstrom, Nathan, et al.
Publicado: (2022)

The year in cardiovascular medicine 2022: the top 10 papers in heart failure and cardiomyopathies
por: de Boer, Rudolf A, et al.
Publicado: (2023)

Spot Urinary Sodium as a Biomarker of Diuretic Response in Acute Heart Failure
por: Oliva‐Damaso, Nestor, et al.
Publicado: (2023)

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced
por: Zannad, Faiez, et al.
Publicado: (2020)

Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it
por: Ahmad, Faheem A., et al.
Publicado: (2019)

Call for New Therapies in Heart Failure: How Cardiology Can Learn From Oncology
por: Maurer, Mathew S.
Publicado: (2019)

Renoprotective effect of tolvaptan in patients with new‐onset acute heart failure
por: Kin, Hiromi, et al.
Publicado: (2020)

COVID-19 in Ethiopia: A contextual approach to explaining its slow growth
por: Wondimagegn, Dawit, et al.
Publicado: (2020)

Remote Monitoring of Heart Failure in Patients with Implantable Cardioverter-Defibrillators: Current Status and Future Needs
por: Theuns, Dominic A. M. J., et al.
Publicado: (2021)

What should the C (‘congestive heart failure’) represent in the CHA(2)DS(2)‐VASc score?
por: Mulder, Bart A., et al.
Publicado: (2020)

Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?
por: Pitt, Bertram, et al.
Publicado: (2022)

Due Diligence of a Diastolic Index as a Prognostic Factor in Heart Failure with Preserved Ejection Fraction
por: Hoshida, Shiro
Publicado: (2023)

Reconstruction of Severely Crushed Fingertip Amputations with Basic Fibroblast Growth Factor Slow Release System
por: Kusuhara, Hirohisa, et al.
Publicado: (2017)

Design of a prospective patient‐level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure
por: Packer, Milton, et al.
Publicado: (2020)

Temporal Change in Renoprotective Effect of Tolvaptan on Patients with Heart Failure: AURORA Study
por: Nishino, Masami, et al.
Publicado: (2022)

Renoprotection by long‐term low‐dose tolvaptan in patients with heart failure and hyponatremia
por: Oka, Tatsufumi, et al.
Publicado: (2021)

Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study
por: Palevsky, Paul M, et al.
Publicado: (2009)

Dialysis dose in acute kidney injury: no time for therapeutic nihilism – a critical appraisal of the Acute Renal Failure Trial Network study
por: Ronco, Claudio, et al.
Publicado: (2008)

Rapid evidence‐based sequencing of foundational drugs for heart failure and a reduced ejection fraction
por: Packer, Milton, et al.
Publicado: (2021)

Potassium binders for patients with heart failure? The real enlightenment of the DIAMOND trial( )
por: Packer, Milton
Publicado: (2022)

Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial
por: Butler, Javed, et al.
Publicado: (2021)

Activating mutations and senescence secretome: new insights into HER2 activation, drug sensitivity and metastatic progression
por: Acharyya, Swarnali
Publicado: (2013)

Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction
por: Butler, Javed, et al.
Publicado: (2022)

Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs
por: Packer, Milton
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_60vtnbiktcp8m4rhg5j6of12ne